NCT04362410View on ClinicalTrials.gov

Tezepelumab Phase 1 PK Study in Healthy Chinese Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

May 18, 2020

Primary Completion Date

October 9, 2020

Study Completion Date

October 9, 2020

Conditions
Healthy Subjects
Interventions
BIOLOGICAL

Experimental: Tezepelumab

Tezepelumab single dose subcutaneously injection.

OTHER

Placebo

Placebo single dose subcutaneously injection.

Trial Locations (1)

330006

Research Site, Nanchang

Sponsors

Lead Sponsor

AstraZeneca

Collaborators (1)

Amgen
All Listed Sponsors
collaborator

Amgen

INDUSTRY

lead

AstraZeneca

INDUSTRY